Characterization of the Sleep-Wake Cycle in Traumatic Brain Injury Patients with a Disorder of Consciousness (SLEEPDOC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jacques LUAUTE, professor
- Phone Number: 33 04.78.86.51.87
- Email: jacques.luaute@chu-lyon.fr
Study Contact Backup
- Name: Anne-Laure CHARLOIS
- Email: anne-laure.charlois@chu-lyon.fr
Study Locations
-
-
-
Bron, France, France, 69500
- Hôpital Neurologique Pierre Wertheimer, Service de Réanimation Polyvalente Neurologique
-
Contact:
- Jacques LUAUTE
- Phone Number: +33 04.78.86.51.87
- Email: jacques.luaute@chu-lyon.fr
-
Contact:
- Jacques LUAUTE
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Admission to the Post-Resuscitation Rehabilitation Unit or the Neurological Intensive Care Unit
- Consciousness disorders: Vegetative State or Minimally Conscious State (according to the CRS-R)
- Traumatic brain injury
- Patient aged 18 years or older
- Presence of relatives able to express non-opposition to the study
- Subjects affiliated with a social security scheme (or beneficiaries)
Exclusion Criteria:
- Admission for status epilepticus
- Individuals admitted to a healthcare or social care facility for purposes other than research
- Adults under legal protection measures (guardianship, conservatorship)
- Individuals not affiliated with a social security scheme or not benefiting from a similar scheme
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Patients in a vegetative state
|
actimetry will be performed continuously during these 104 hours.
The subjective assessments of the patient's awake/sleep state will be collected every 2 hours during the night and at least 3 times during the day, for a total of at least 8 assessments per 24-hour period, over a duration of 104 consecutive hours (slightly more than 4 days, starting at midnight and ending at 8 :00 AM, to cover 4 full days and 4 full nights).
MOCA : Montreal Cognitive Assessment
SF-36 The Short Form (36)
CRS-R (Coma Recovery Scale-Revised)
GOSE (Glasgow Outcome Scale-Extended)
GCS (Glasgow Coma Scale)
|
|
Experimental: Patients in a minimally conscious state
|
actimetry will be performed continuously during these 104 hours.
The subjective assessments of the patient's awake/sleep state will be collected every 2 hours during the night and at least 3 times during the day, for a total of at least 8 assessments per 24-hour period, over a duration of 104 consecutive hours (slightly more than 4 days, starting at midnight and ending at 8 :00 AM, to cover 4 full days and 4 full nights).
MOCA : Montreal Cognitive Assessment
SF-36 The Short Form (36)
CRS-R (Coma Recovery Scale-Revised)
GOSE (Glasgow Outcome Scale-Extended)
GCS (Glasgow Coma Scale)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Subjective assessments
Time Frame: during 104 consecutive hours after enrollment
|
during 104 consecutive hours after enrollment
|
|
Actimetry
Time Frame: during 104 consecutive hours after enrollment
|
during 104 consecutive hours after enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Coma Recovery Scale-Revised
Time Frame: once a day for 6 to 5 days
|
once a day for 6 to 5 days
|
|
Coma Recovery Scale-Revised
Time Frame: 3 months after the start of study
|
3 months after the start of study
|
|
Coma Recovery Scale-Revised
Time Frame: 6 months after the start of study
|
6 months after the start of study
|
|
Glasgow Coma Scale assessment
Time Frame: once a day for 6 to 5 days
|
once a day for 6 to 5 days
|
|
Glasgow Coma Scale assessment
Time Frame: 3 months after the start of study
|
3 months after the start of study
|
|
Glasgow Coma Scale assessment
Time Frame: 6 months after the start of study
|
6 months after the start of study
|
|
Glasgow Outcome Scale-Extended assessment
Time Frame: 6 months after the start of study
|
6 months after the start of study
|
|
Glasgow Outcome Scale-Extended assessment
Time Frame: 3 months after the start of study
|
3 months after the start of study
|
|
Montreal Cognitive Assessment
Time Frame: 3 months after the start of study
|
3 months after the start of study
|
|
Montreal Cognitive Assessment
Time Frame: 6 months after the start of study
|
6 months after the start of study
|
|
Short Form 36 assessment
Time Frame: 3 months after the start of the study
|
3 months after the start of the study
|
|
Short Form 36 assessment
Time Frame: 6 months after the start of study
|
6 months after the start of study
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jacques LUAUTE, Professor, Hôpital Neurologique Pierre Wertheimer, Service de Service de Rééducation Post-Réanimation
- Principal Investigator: Florent GOBERT, Doctor, Hôpital Neurologique Pierre Wertheimer, Service de Réanimation Polyvalente Neurologique
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 69HCL24_0936
- 2024-A02567-40 (Other Identifier: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.